Analysis of Novel Prostate Cancer Biomarkers and their Predictive Utility in an Active Surveillance Protocol
Annual summary rept. 1 May 2013-30 Apr 2014
MASSACHUSETTS GENERAL HOSPITAL BOSTON
Pagination or Media Count:
The Research Project supported by this DOD PCRP Physician Research Training Award investigates novel biomarkers for prostate cancer and investigation of Active Surveillance of low risk prostate cancer. In the third year of this award I have continued to investigate potential prostate cancer markers using Western Blot, ELISA, and RCC. Proteins that I have investigated include Semenogelin-2, Lactoylglutathione Lyase, Hepsin, Leukocyte Elastase Inhibitor SERPINB1, Alpha-1-Antichymotrypsin SerpinA3, Growth-Inhibiting Protein 12 GIP 12, Prohibitin, Radixin, Taldo1, Fructose-Bisphosphate Aldolase A, Lactate Dehydrogenase A, CD63, Cytochrome C, Ras-related protein RAB-3A, Macrophage Capping Protein, 10kd Heat Shock Protein, Annexin A3, Sorbitol Dehydrogenase, Fibrinogen Beta Chain Precursor, Creatine Kinase B-Type, Annexin A1, Cystatin B, and AZI. We have continued to have promising results in TIMP-1 and now also Seminogelin-2. In addition to our laboratory work, we have built on our previous work in further developing our clinical database and evaluating our cohort of men on active surveillance AS for low risk prostate cancer. Our database now consists of over 600 men on active surveillance and we recently submitted our manuscript for publication describing our initial cohort of 469 men.
- Medicine and Medical Research